Oncolytics Biotech IncNASDAQ:ONCYView on Canadian Exchange
- LAST PRICE1.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.0200/ 10
- Ask / Lots1.0600/ 1
- Open / Previous Close1.0800 / 1.0400
- Day Range
- 52 Week Range
- Volume94,831
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ONCY |
|---|---|---|
| 09:32 ET | 41361 | 1.0601 |
| 09:36 ET | 250 | 1.0565 |
| 09:38 ET | 150 | 1.06 |
| 09:39 ET | 1550 | 1.05 |
| 09:56 ET | 100 | 1.04 |
| 09:57 ET | 1500 | 1.04 |
| 10:15 ET | 125 | 1.0356 |
| 10:19 ET | 141 | 1.0304 |
| 10:35 ET | 100 | 1.0332 |
| 10:37 ET | 100 | 1.04 |
| 10:55 ET | 200 | 1.035 |
| 11:02 ET | 250 | 1.0382 |
| 11:06 ET | 100 | 1.035 |
| 11:09 ET | 110 | 1.03 |
| 11:15 ET | 1775 | 1.035 |
| 11:20 ET | 100 | 1.034 |
| 11:24 ET | 1700 | 1.03 |
| 11:29 ET | 7484 | 1.03 |
| 11:33 ET | 1500 | 1.0321 |
| 11:42 ET | 100 | 1.0399 |
| 12:21 ET | 100 | 1.0399 |
| 12:23 ET | 961 | 1.0392 |
| 12:54 ET | 100 | 1.0399 |
| 12:59 ET | 2000 | 1.0399 |
| 01:01 ET | 100 | 1.035 |
| 01:06 ET | 1600 | 1.0317 |
| 01:12 ET | 2000 | 1.0301 |
| 01:19 ET | 5000 | 1.03 |
| 01:21 ET | 100 | 1.03 |
| 01:26 ET | 100 | 1.04 |
| 01:28 ET | 2000 | 1.0399 |
| 01:51 ET | 500 | 1.035 |
| 02:42 ET | 100 | 1.0301 |
| 02:44 ET | 400 | 1.0346 |
| 03:03 ET | 1190 | 1.0305 |
| 03:16 ET | 2600 | 1.03 |
| 03:25 ET | 1545 | 1.0301 |
| 03:38 ET | 481 | 1.03 |
| 03:48 ET | 227 | 1.035 |
| 03:59 ET | 661 | 1.04 |
Jul 24, 2024
Oncolytics Biotech(R) to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights, from 7:00AM ET on Wednesday Jul 24, 2024 by Dow Jones
7:00AM ET on Wednesday Jul 24, 2024 by Dow JonesOncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights, from 7:00AM ET on Wednesday Jul 24, 2024 by Dow Jones
7:00AM ET on Wednesday Jul 24, 2024 by Dow Jones
Jun 27, 2024
Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program, from 7:00AM ET on Thursday Jun 27, 2024 by Dow Jones
7:00AM ET on Thursday Jun 27, 2024 by Dow JonesOncolytics Biotech(R) Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program, from 7:00AM ET on Thursday Jun 27, 2024 by Dow Jones
7:00AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oncolytics Biotech Inc | 108.0M | -3.6x | --- |
Immix Biopharma Inc | 56.8M | -2.4x | --- |
Anebulo Pharmaceuticals Inc | 57.1M | -6.1x | --- |
Aerovate Therapeutics Inc | 55.3M | -0.7x | --- |
Mural Oncology PLC | 58.6M | -0.3x | --- |
Rallybio Corp | 55.1M | -0.7x | --- |
Company Information
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Contact Information
- Headquarters
- 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7CALGARY, AB, Canada T2R 0C5
- Phone
- 403-670-7377
- Fax
- 403-283-0858
Executives
- Chairman of the Board, Interim Chief Executive Officer
- Wayne Pisano
- Chief Financial Officer
- Kirk Look
- Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.
- Andrew Guttadauro
- Vice President - Product Development
- Allison Hagerman
- Chief Medical Officer of Oncolytics Biotech (U.S.)
- Thomas Heineman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $78.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 76.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.90 |
EPS | $-0.29 |
Book Value | $0.27 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
